MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
2.640
+0.120
+4.76%
After Hours: 2.640 0 0.00% 16:04 05/20 EDT
OPEN
2.530
PREV CLOSE
2.520
HIGH
2.700
LOW
2.530
VOLUME
44.22K
TURNOVER
--
52 WEEK HIGH
4.180
52 WEEK LOW
1.765
MARKET CAP
11.70M
P/E (TTM)
-0.9868
1D
5D
1M
3M
1Y
5Y
1D
Kiora Pharmaceuticals files to sell 11.8M shares of common stock for holders
TipRanks · 2d ago
Kiora Pharmaceuticals Files Prospectus For Offering 11.797M Common Stock On Behalf Of Selling Shareholders
Benzinga · 2d ago
KIORA PHARMACEUTICALS INC - FILES PROSPECTUS FOR RESALE OF UP TO 11.8 MLN SHARES BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 2d ago
Weekly Report: what happened at KPRX last week (0511-0515)?
Weekly Report · 2d ago
Weekly Report: what happened at KPRX last week (0504-0508)?
Weekly Report · 05/11 10:30
Analysts Are Bullish on Top Healthcare Stocks: Kiora Pharmaceuticals (KPRX), Myomo (MYO)
TipRanks · 05/09 21:30
Kiora Pharmaceuticals Q1 EPS $(0.58) Beats $(0.71) Estimate
Benzinga · 05/08 13:54
Kiora Pharmaceuticals GAAP EPS of -$0.58
Seeking Alpha · 05/08 11:25
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.